Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 676 participants.
Also called NCT02227550
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 676 participants
- Sponsor
- Registry
-
NCT02227550 -
2014-002442-45
-
- Other papers using this trial's data
- MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Austria, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02227550. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
- Acronym
- AXAFA
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Vitamin K antagonist
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Atrial Fibrillation Network
- Collaborator
- Bristol-Myers Squibb
- Collaborator
- Pfizer
- Collaborator
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Record details
- Record id
cardio:ct-nct02227550- Content hash
1bfe02e38be512763bb0ddc965305df2ebd09ed36a03e4bc9572848719da4869